Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Gets Price Target Cut from Mizuho

Corbus Pharmaceuticals (NASDAQ:CRBP) had its target price reduced by Mizuho from $24.00 to $23.00 in a research note released on Thursday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on CRBP. Oppenheimer reissued an “outperform” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, September 14th. Finally, Wall Street Zen cut shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.67.

Corbus Pharmaceuticals Trading Down 0.6%

Shares of CRBP stock traded down $0.02 during trading hours on Thursday, hitting $3.39. 573,365 shares of the company were exchanged, compared to its average volume of 1,154,452. The business has a 50 day moving average of $5.67 and a two-hundred day moving average of $8.34. Corbus Pharmaceuticals has a 52 week low of $2.81 and a 52 week high of $12.88. The company has a market capitalization of $69.87 million, a PE ratio of -0.56 and a beta of 2.80.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.54). On average, research analysts forecast that Corbus Pharmaceuticals will post -6.35 EPS for the current year.

Insider Buying and Selling at Corbus Pharmaceuticals

In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $4.10, for a total value of $1,742,500.00. Following the completion of the transaction, the insider owned 1,919,971 shares in the company, valued at $7,871,881.10. This trade represents a 18.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRBP. Orbimed Advisors LLC increased its position in shares of Corbus Pharmaceuticals by 8.8% during the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after purchasing an additional 140,000 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Corbus Pharmaceuticals by 288.4% in the 3rd quarter. Marshall Wace LLP now owns 308,138 shares of the biopharmaceutical company’s stock valued at $2,102,000 after buying an additional 228,807 shares during the last quarter. Exome Asset Management LLC grew its stake in shares of Corbus Pharmaceuticals by 67.8% in the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after buying an additional 94,593 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Corbus Pharmaceuticals by 76.6% in the first quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 59,248 shares in the last quarter. Finally, Seven Fleet Capital Management LP grew its stake in shares of Corbus Pharmaceuticals by 51.0% in the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 28,937 shares in the last quarter. 64.64% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals News Roundup

These are some of the CRBP news items that stood out recently:

• Positive Sentiment: Mizuho maintained an Outperform rating and lowered its target only modestly, from $24 to $23. HC Wainwright also reiterated its Buy rating and $35 target, signaling substantial potential upside in analysts’ view, though targets are not guarantees. Corbus Pharmaceuticals Stock Price Target Lowered at Mizuho
• Negative Sentiment: The forecast changes were mixed but included notable reductions: HC Wainwright lowered its Q4 2026 and full-year 2026 EPS estimates, as well as estimates for 2029 and 2030. It raised its 2027 and 2028 estimates, but the continuing projected losses underline the company’s ongoing earnings risk. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Recent results add pressure: Corbus reported a quarterly loss of $1.81 per share, worse than the $1.27-per-share loss analysts expected. Taken together with lowered near-term forecasts, this may weigh on sentiment despite the bullish ratings and targets.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.